Literature DB >> 31279973

DNA damage response and repair in ovarian cancer: Potential targets for therapeutic strategies.

Mohammad Mirza-Aghazadeh-Attari1, Caspian Ostadian2, Amir Ata Saei3, Ainaz Mihanfar4, Saber Ghazizadeh Darband5, Shirin Sadighparvar6, Mojtaba Kaviani7, Hossein Samadi Kafil8, Bahman Yousefi9, Maryam Majidinia10.   

Abstract

Ovarian cancer is among the most lethal gynecologic malignancies with a poor survival prognosis. The current therapeutic strategies involve surgery and chemotherapy. Research is now focused on novel agents especially those targeting DNA damage response (DDR) pathways. Understanding the DDR process in ovarian cancer necessitates having a detailed knowledge on a series of signaling mediators at the cellular and molecular levels. The complexity of the DDR process in ovarian cancer and how this process works in metastatic conditions is comprehensively reviewed. For evaluating the efficacy of therapeutic agents targeting DNA damage in ovarian cancer, we will discuss the components of this system including DDR sensors, DDR transducers, DDR mediators, and DDR effectors. The constituent pathways include DNA repair machinery, cell cycle checkpoints, and apoptotic pathways. We also will assess the potential of active mediators involved in the DDR process such as therapeutic and prognostic candidates that may facilitate future studies.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  DNA damage response; DNA repair; Ovarian cancer

Mesh:

Substances:

Year:  2019        PMID: 31279973     DOI: 10.1016/j.dnarep.2019.06.005

Source DB:  PubMed          Journal:  DNA Repair (Amst)        ISSN: 1568-7856


  6 in total

1.  Analysis of Omics Data Reveals Nucleotide Excision Repair-Related Genes Signature in Highly-Grade Serous Ovarian Cancer to Predict Prognosis.

Authors:  Danian Dai; Qiang Li; Pengfei Zhou; Jianjiang Huang; Hongkai Zhuang; Hongmei Wu; Bo Chen
Journal:  Front Cell Dev Biol       Date:  2022-06-13

2.  GAS6/AXL Inhibition Enhances Ovarian Cancer Sensitivity to Chemotherapy and PARP Inhibition through Increased DNA Damage and Enhanced Replication Stress.

Authors:  Mary M Mullen; Elena Lomonosova; Michael D Toboni; Alyssa Oplt; Emily Cybulla; Barbara Blachut; Peinan Zhao; Hollie Noia; Daniel Wilke; Erinn B Rankin; Lindsay M Kuroki; Andrea R Hagemann; Ian S Hagemann; Carolyn K McCourt; Premal H Thaker; David G Mutch; Matthew A Powell; Nima Mosammaparast; Alessandro Vindigni; Katherine C Fuh
Journal:  Mol Cancer Res       Date:  2021-10-20       Impact factor: 6.333

3.  SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers.

Authors:  Zhen Lu; Weiqun Mao; Hailing Yang; Janice M Santiago-O'Farrill; Philip J Rask; Jayanta Mondal; Hu Chen; Cristina Ivan; Xiuping Liu; Chang-Gong Liu; Yuanxin Xi; Kenta Masuda; Eli M Carrami; Meng Chen; Yitao Tang; Lan Pang; David S Lakomy; George A Calin; Han Liang; Ahmed A Ahmed; Hariprasad Vankayalapati; Robert C Bast
Journal:  J Clin Invest       Date:  2022-06-01       Impact factor: 19.456

Review 4.  DNA Repair and Ovarian Carcinogenesis: Impact on Risk, Prognosis and Therapy Outcome.

Authors:  Kristyna Tomasova; Andrea Cumova; Karolina Seborova; Josef Horak; Kamila Koucka; Ludmila Vodickova; Radka Vaclavikova; Pavel Vodicka
Journal:  Cancers (Basel)       Date:  2020-06-28       Impact factor: 6.639

5.  Effects of Wee1 inhibitor adavosertib on patient-derived high-grade serous ovarian cancer cells are multiple and independent of homologous recombination status.

Authors:  Pia Roering; Arafat Siddiqui; Vanina D Heuser; Swapnil Potdar; Piia Mikkonen; Jaana Oikkonen; Yilin Li; Sanna Pikkusaari; Krister Wennerberg; Johanna Hynninen; Seija Grenman; Kaisa Huhtinen; Annika Auranen; Olli Carpén; Katja Kaipio
Journal:  Front Oncol       Date:  2022-08-23       Impact factor: 5.738

6.  Theasaponin E1 Inhibits Platinum-Resistant Ovarian Cancer Cells through Activating Apoptosis and Suppressing Angiogenesis.

Authors:  Bo Li; Tuantuan Tong; Ning Ren; Gary O Rankin; Yon Rojanasakul; Youying Tu; Yi Charlie Chen
Journal:  Molecules       Date:  2021-03-17       Impact factor: 4.927

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.